NCI’s cancer screening trials may be falling victim to the COVID-19 pandemic.
Kevan Shokat, a professor of cellular and molecular pharmacology at UC San Francisco, has won the second annual Stephenson Global Prize for research in pancreatic cancer.
NCI will form an ad hoc committee to review screening trials
The future of ECOG-ACRIN's slowly-accruing TMIST is in question
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
FDA has granted an accelerated approval to dostarlimab-gxly (Jemperli), making it the first and only immunotherapy approved in the U.S. for adults with locally advanced rectal cancers.
“As Iowa goes, so goes the nation.”
Throughout my career as a physician and scientist, I’ve seen ideas once considered impossible become breakthroughs that save lives. They happened because talented scientists had the resources, institutions, and sustained support to pursue ambitious ideas. Most importantly, they knew patients could not afford to wait.
The National Academy of Medicine announced the election of 90 regular members and 10 international members during its annual meeting Oct. 19.
Cancer therapy has become increasingly personalized. Biomarker-driven treatment selection, targeted therapies, and immunotherapy have transformed outcomes across many tumor types and demonstrated the power of matching the right treatment to the right patient.
